-

Midol® Encourages Menstruators to Find Comfort in Speaking Up and Acknowledging ‘The Real Reason’ Behind Changing Plans When Period Symptoms Strike

‘The Real Reason’ is a social experiment that unveils the power that comes from speaking up and unapologetically seeking relief from period symptoms

WHIPPANY, N.J.--(BUSINESS WIRE)--Midol®, the #1 Period Relief brand1 by Bayer, is launching The Real Reason: A Social Experiment that reinforces to people with periods and those who support them that period symptoms are not something to push through. In a recent survey, only about half of people with periods feel it is socially acceptable to cancel or reschedule social (54%)2 and academic (50%) obligations because of period symptoms.3 No more.

Midol® wants to create an environment that encourages menstruators to reach for relief and openly recognize their period symptoms as a real reason for taking time to themselves. After putting an end to period apologies with last year’s No Apologies. Period. movement, this social experiment inspires sharing the real reason as the next step to ending period stigmas. There is power in sharing and owning the truth. There is power in finding comfort in that honesty.

An extension of the Comfort is Power campaign launched earlier this year, Midol’s The Real Reason, captures reactions from friends, family, school, and work colleagues to real menstruators “calling out” of different social or work commitments due to period symptoms instead of using a fake or more “acceptable” reason. The result was an overwhelming response of understanding and support, empowering the honest individuals to do what’s necessary to take care of their bodies and achieve the comfort they need.

“Midol® is working to reinforce that there is no shame in talking about period symptoms and, more importantly, in speaking out when they strike. We want menstruators to feel the power in addressing their needs and the even greater power that comes from knowing their community will support them when they do,” said Kelly Fanning, General Manager & Vice President of Pain and Cardio at Bayer Consumer Health U.S. “Our hope is this campaign helps normalize the conversation around period symptoms and help menstruators realize that speaking and acting on your period truth is powerful.”

While the period positivity movement has made strides in normalizing taboo topics, they largely remain sources of individual discomfort. Only 43% of menstruators know how to have a comfortable, open dialogue about their period with peers.2 By highlighting real menstruators speaking their period truth to friends, family and colleagues, Midol® hopes to continue breaking down toxic suppressive cycle and perception that period symptoms are an unacceptable reason to take the time you need.

“As menstruators, we feel pressure to hide or make excuses for our periods. For anyone who has experienced the debilitating and annoying period symptoms, they are not something you can just easily push through and ignore,” said Midol® Partner Dr. Charis Chambers, OBGYN. “This social experiment showcases the modern reality menstruators face and society’s reaction to the real reasons for needing a break. I’m honored to support Midol® in creating a world where menstruators aren’t embarrassed of their bodies and feel the need to minimize period symptoms. Together we are celebrating the power in actively and unapologetically owning your period and seeking the relief you need.”

Watch The Real Reason: A Social Experiment at www.Midol.com/therealreason and @Midol on Instagram. Follow @Midol on Instagram and share an instance where you gave The Real Reason for putting your comfort first using #TheRealReason.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

_______________________________________
1
#1 OTC brand based on highest dollar and unit sales in Period Category, IRI L52WK ending 05/29/22 Total US – MULO
2 This poll was conducted by Morning Consult on behalf of Bayer between April 23 – April 25, 2022, among a national sample of 1117 US adults who menstruate. The interviews were conducted online and the data were weighted to approximate a target sample based on age, race/ethnicity, educational attainment, and region. Results from the full survey have a margin of error of +/- 3 percentage points.
3 This poll was conducted by Morning Consult on behalf of Bayer between April 23 – April 25, 2022, among a subset of self-identified students (n=124) of a national sample of 1117 US adults who menstruate. The interviews were conducted online and the data were weighted to approximate a target sample based on age, race/ethnicity, educational attainment, and region. Results from the full survey have a margin of error of +/- 3 percentage points.

Contacts

Christin Miller
Director, Strategic Communications, Brand and External PR Consumer Health
christin.miller@bayer.com

Keri Madonna
Vice President, Media, Lippe Taylor Group
kmadonna@lippetaylor.com

Emma McCormick
Account Supervisor, Media & Engagement, twelvenote
emccormick@twelvenote.com

Bayer


Release Versions

Contacts

Christin Miller
Director, Strategic Communications, Brand and External PR Consumer Health
christin.miller@bayer.com

Keri Madonna
Vice President, Media, Lippe Taylor Group
kmadonna@lippetaylor.com

Emma McCormick
Account Supervisor, Media & Engagement, twelvenote
emccormick@twelvenote.com

More News From Bayer

Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims

ST. LOUIS--(BUSINESS WIRE)--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class. “We are pleased the Court granted preliminary approval of the class settlement, which is designed to resolve current and potential future Roundup claims relating to...

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expands MRXperion’s labeled field strength compatibility to support magnetic resonance imaging (MRI) scanners with magnetic...

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose....
Back to Newsroom